TY - JOUR
T1 - Analyses of methadone and other drugs in maternal and neonatal body fluids
T2 - Use in evaluation of symptoms in a neonate of mother maintained on methadone
AU - Kreek, M. J.
AU - Schecter, A.
AU - Gutjahr, C. L.
AU - Bowen, D.
AU - Field, F.
AU - Queenan, J.
AU - Merkatz, I.
N1 - Funding Information:
*This article is based upon research activities supported in part through a grant from the New York State Drug Addiction Control Commission to The Rockefeller University, and by NIMH H80 Grant to The Kentucky Region 8 Mental Health Program. Conclusions herein are not necessarily those of the Drug Addiction Control Commission. Dr. Kreek is a recipient of a Career Scientist award of the Health Research Council of the City of New York. **A. Schecter is presently with the N. Y. Downstate Medical Center. ***I. Merkatz is presently with the Case-Western Medical Center.
PY - 1974
Y1 - 1974
N2 - A former heroin addict treated with methadone maintenance throughout pregnancy, with rapid dose reduction from 110 mg to 9 mg during the last five weeks pre-partum, was evaluated in late pregnancy, at time of labor and delivery, and post-partum; her child was also evaluated. Using gas and thin-layer chromatography and mass spectroscopy, methadone levels were measured, and other drugs looked for in (1) plasma during late pregnancy, (2) mixed cord blood, (3) amniotic fluid at delivery, (4) maternal plasma and milk post-partum (on 50 mg methadone), (5) neonatal plasma and urine. Low levels of methadone were present in amniotic fluid and neonatal urine but not in mixed cord blood or neonatal plasma. Levels of methadone present in breast milk during moderate dose maintenance were also low. Unexpectedly, pentobarbital was identified in amniotic fluid. Neonatal infection was also diagnosed. Multiple factors may have contributed to symtoms observed in the neonate.
AB - A former heroin addict treated with methadone maintenance throughout pregnancy, with rapid dose reduction from 110 mg to 9 mg during the last five weeks pre-partum, was evaluated in late pregnancy, at time of labor and delivery, and post-partum; her child was also evaluated. Using gas and thin-layer chromatography and mass spectroscopy, methadone levels were measured, and other drugs looked for in (1) plasma during late pregnancy, (2) mixed cord blood, (3) amniotic fluid at delivery, (4) maternal plasma and milk post-partum (on 50 mg methadone), (5) neonatal plasma and urine. Low levels of methadone were present in amniotic fluid and neonatal urine but not in mixed cord blood or neonatal plasma. Levels of methadone present in breast milk during moderate dose maintenance were also low. Unexpectedly, pentobarbital was identified in amniotic fluid. Neonatal infection was also diagnosed. Multiple factors may have contributed to symtoms observed in the neonate.
UR - http://www.scopus.com/inward/record.url?scp=0016329051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016329051&partnerID=8YFLogxK
U2 - 10.3109/00952997409011033
DO - 10.3109/00952997409011033
M3 - Article
C2 - 4619541
AN - SCOPUS:0016329051
SN - 0095-2990
VL - 1
SP - 409
EP - 419
JO - American Journal of Drug and Alcohol Abuse
JF - American Journal of Drug and Alcohol Abuse
IS - 3
ER -
